Morningstar enters the back half of the week in a very different position than it faced heading into Tuesday's earnings — the put-heavy defensive posture that defined the pre-print setup has given way to a sharp rally and a notable short squeeze.
The stock gained 6.4% on Tuesday and is up 17% on the week to $194.12, its best seven-day stretch in months. That move followed Q2 results reported on July 29, which appear to have wrong-footed the options traders who spent the prior two weeks stacking puts. The put/call ratio peaked at 3.997 on July 21 — the 52-week high — before easing to 3.42 by Tuesday's close. It remains well above its 20-day mean of 2.86, so defensive positioning hasn't fully unwound, but the direction of travel is clearly toward normalization.
The borrow market confirms the reversal story. Short interest has fallen 6.8% in a week, dropping from roughly 1.77 million shares to 1.48 million, now at 3.6% of the free float — down from a peak near 2.1 million shares in early July. That early-July spike looks like positioning ahead of earnings that is now being covered. Availability remains extraordinarily loose at nearly 3,000%, meaning shares available to borrow outnumber current short interest by a factor of almost 30. Borrowing costs have dropped to 0.37%, down 28% on the week, the lowest reading in the 30-day window. There is no squeeze pressure here — just an orderly unwinding of a trade that didn't pay off.
The peer picture sharpens the divergence. Close comparable FDS also surged, gaining 6.8% on the day and nearly 15% on the week — suggesting a broader re-rating of financial data names rather than a purely Morningstar-specific event. In contrast, SPGI and MCO both fell on the day, down 3.5% and 0.4% respectively, and are slightly negative on the week. The move in MORN and FDS looks more like a reaction to earnings-driven relief than a sector-wide bid.
Street positioning remains constructive but stretched relative to current prices. The mean analyst price target is $226, implying roughly 16% upside from Tuesday's close — tighter than it looked a week ago given the stock has rallied 25% over the past month. The most recent formal analyst move came from UBS on July 7, when Alex Kramm trimmed the price target from $280 to $260 while keeping a Buy rating. BMO Capital has maintained an Outperform but has been cutting targets steadily since mid-2025, with the current figure at $193 — now below the stock's close, a notable situation worth flagging. The bull case centers on mid-to-high 20% margin expansion and PitchBook growth; the bear case highlights decelerating revenue growth and earnings-per-share estimates at risk of a 10% cut. With the stock now at $194 and BMO's target at $193, that bear case has some near-term relevance regardless of the post-earnings bounce.
The ORTEX short score has eased to 43.8 from a recent high of 48.4 on July 22, consistent with the unwinding dynamic. Factor scores show a strong dividend rank (99th percentile) but more modest momentum and earnings signals — the 30-day EPS momentum sits in the 41st percentile, suggesting the street hasn't dramatically revised upward yet in the wake of the print.
What to watch next is whether the analyst community responds to the earnings release with material target revisions — the gap between UBS at $260, BMO at $193, and the stock now trading at $194 makes the next round of post-print notes a genuine price-discovery event rather than a rubber stamp.
See the live data behind this article on ORTEX.
Open MORN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
